Table 2.
Without MRA | With MRA | p-value | |
---|---|---|---|
n | 170 | 303 | |
Age (years) | 70.7 | 68.4 | 0.017 |
Male sex (%) | 56.5 | 69.6 | 0.004 |
African American (%) | 32.9 | 32.7 | 0.953 |
Current smoker (%) | 17.1 | 27.5 | 0.011 |
Diabetes (%) | 37.7 | 38.6 | 0.836 |
Hypertension (%) | 91.8 | 89.1 | 0.354 |
Ankle–brachial index | 0.65 | 0.68 | 0.135 |
Body mass index (kg/m2) | 29.4 | 29.4 | 0.984 |
Normalized mean plaque area | 0.7 | 0.7 | 0.811 |
Mean percent lumen area | 0.3 | 0.3 | 0.814 |
Leg symptoms | |||
Asymptomatic (%) | 24.1 | 17.8 | 0.101 |
Intermittent claudication (%) | 18.2 | 26.7 | 0.037 |
Pain on exertion and rest (%) | 30.6 | 25.1 | 0.196 |
Atypical exertional leg pain (%) | 18.2 | 20.5 | 0.559 |
Exertional leg pain carry on (%) | 8.8 | 9.9 | 0.702 |
Data shown are mean values.
A total of 241 participants with MRA data and 71 participants without MRA data had a glomerular filtration rate measured as part of the research protocol.